Bionano Genomics Stock Buy Hold or Sell Recommendation
| BNGO Stock | USD 5.19 0.56 9.74% |
Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Bionano Genomics is 'Strong Sell'. The recommendation algorithm takes into account all of Bionano Genomics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Bionano Genomics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide. In addition, we conduct extensive research on individual companies such as Bionano and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Bionano |
Execute Bionano Genomics Buy or Sell Advice
The Bionano recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Bionano Genomics. Macroaxis does not own or have any residual interests in Bionano Genomics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Bionano Genomics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Bionano Genomics Trading Alerts and Improvement Suggestions
| Bionano Genomics generated a negative expected return over the last 90 days | |
| Bionano Genomics has high historical volatility and very poor performance | |
| Bionano Genomics has a very high chance of going through financial distress in the upcoming years | |
| Bionano Genomicshas 20,490,896 shares shorted by Bionano Genomics investors is about 800% of outstending shares | |
| The company reported the previous year's revenue of 36.12 M. Net Loss for the year was (232.49 M) with profit before overhead, payroll, taxes, and interest of 10.6 M. | |
| Bionano Genomics currently holds about 187.34 M in cash with (125.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65. | |
| Latest headline from news.google.com: BioNano Genomics Executes Significant Reverse Stock Split - TipRanks |
Bionano Genomics Returns Distribution Density
The distribution of Bionano Genomics' historical returns is an attempt to chart the uncertainty of Bionano Genomics' future price movements. The chart of the probability distribution of Bionano Genomics daily returns describes the distribution of returns around its average expected value. We use Bionano Genomics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Bionano Genomics returns is essential to provide solid investment advice for Bionano Genomics.
| Mean Return | -1.3 | Value At Risk | -14.46 | Potential Upside | 11.87 | Standard Deviation | 9.02 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Bionano Genomics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Bionano Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Bionano Genomics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Bionano Genomics back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Archford Capital Strategies, Llc | 2024-12-31 | 69.6 K | Susquehanna International Group, Llp | 2024-09-30 | 49.2 K | Inspire Advisors, Llc | 2024-09-30 | 37.3 K | Golden State Equity Partners | 2024-09-30 | 26.5 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 25.7 K | Two Sigma Investments Llc | 2024-09-30 | 23.7 K | Raymond James Finl Svs Advisors, Inc. | 2024-09-30 | 19.6 K | Tower Research Capital Llc | 2024-09-30 | 17 K | Engineers Gate Manager Lp | 2024-09-30 | 15 K | Vanguard Group Inc | 2024-09-30 | 2.2 M | Geode Capital Management, Llc | 2024-09-30 | 882.9 K |
Bionano Genomics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (4.2M) | (15.9M) | (23.7M) | (4.2M) | (3.7M) | (3.9M) | |
| Investments | (2.4M) | (226.9M) | 116.7M | 24.2M | 27.8M | 29.2M | |
| Change In Cash | 21.1M | (13.9M) | (19.1M) | 12.9M | 11.6M | 12.1M | |
| Net Borrowings | 9.8M | (4.7M) | (15M) | (36K) | (32.4K) | (30.8K) | |
| Free Cash Flow | (38.3M) | (73.4M) | (128.1M) | (126.9M) | (114.2M) | (108.5M) | |
| Depreciation | 1.5M | 3.4M | 9.8M | 13.9M | 16.0M | 16.8M | |
| Other Non Cash Items | 1.3M | 848K | 2.4M | 93.0M | 106.9M | 112.3M | |
| Capital Expenditures | 4.7M | 1.5M | 3.3M | 1.7M | 1.9M | 1.9M | |
| Net Income | (41.1M) | (72.4M) | (132.6M) | (232.5M) | (209.2M) | (198.8M) | |
| End Period Cash Flow | 38.4M | 24.6M | 5.5M | 18.3M | 21.1M | 17.5M | |
| Change To Netincome | 4.1M | 4.8M | 4.2M | 25.2M | 29.0M | 30.4M | |
| Change Receivables | (2.4M) | 2.1M | (493K) | (2.9M) | (2.6M) | (2.5M) |
Bionano Genomics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Bionano Genomics or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Bionano Genomics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Bionano stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.22 | |
β | Beta against Dow Jones | -1.01 | |
σ | Overall volatility | 9.20 | |
Ir | Information ratio | -0.15 |
Bionano Genomics Volatility Alert
Bionano Genomics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Bionano Genomics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Bionano Genomics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Bionano Genomics Fundamentals Vs Peers
Comparing Bionano Genomics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Bionano Genomics' direct or indirect competition across all of the common fundamentals between Bionano Genomics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Bionano Genomics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Bionano Genomics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Bionano Genomics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Bionano Genomics to competition |
| Fundamentals | Bionano Genomics | Peer Average |
| Return On Equity | -1.38 | -0.31 |
| Return On Asset | -0.33 | -0.14 |
| Operating Margin | (2.03) % | (5.51) % |
| Current Valuation | 11.48 M | 16.62 B |
| Shares Outstanding | 2.33 M | 571.82 M |
| Shares Owned By Insiders | 0.15 % | 10.09 % |
| Shares Owned By Institutions | 12.81 % | 39.21 % |
| Number Of Shares Shorted | 20.49 M | 4.71 M |
| Price To Earning | (1.80) X | 28.72 X |
| Price To Book | 0.25 X | 9.51 X |
| Price To Sales | 0.37 X | 11.42 X |
| Revenue | 36.12 M | 9.43 B |
| Gross Profit | 10.6 M | 27.38 B |
| EBITDA | (213.6 M) | 3.9 B |
| Net Income | (232.49 M) | 570.98 M |
| Cash And Equivalents | 187.34 M | 2.7 B |
| Cash Per Share | 0.65 X | 5.01 X |
| Total Debt | 79.41 M | 5.32 B |
| Debt To Equity | 0.04 % | 48.70 % |
| Current Ratio | 7.75 X | 2.16 X |
| Book Value Per Share | 2.10 X | 1.93 K |
| Cash Flow From Operations | (125.18 M) | 971.22 M |
| Short Ratio | 3.81 X | 4.00 X |
| Earnings Per Share | (138.00) X | 3.12 X |
| Target Price | 60.0 | |
| Number Of Employees | 344 | 18.84 K |
| Beta | 2.38 | -0.15 |
| Market Capitalization | 13.4 M | 19.03 B |
| Total Asset | 214.4 M | 29.47 B |
| Retained Earnings | (581.21 M) | 9.33 B |
| Working Capital | 40.09 M | 1.48 B |
| Current Asset | 14.39 M | 9.34 B |
| Current Liabilities | 8.72 M | 7.9 B |
Note: Acquisition by Holmlin R. Erik of 1400000 shares of Bionano Genomics at 1.63 subject to Rule 16b-3 [view details]
Bionano Genomics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Bionano . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Bionano Genomics Buy or Sell Advice
When is the right time to buy or sell Bionano Genomics? Buying financial instruments such as Bionano Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Bionano Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Global Macro ETFs Thematic Idea Now
Global Macro ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Global Macro ETFs theme has 27 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Global Macro ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Bionano Genomics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (138.00) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets | Return On Equity |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.